Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Dexmedetomidine PK in Pediatric CHD
NCT03417999Phase 1Terminated
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Jun 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dexmedetomidine in congenital heart disease (CHD) (2 cohorts), sponsored by Children's Hospital of Philadelphia. Primary endpoints: Number of Samples Obtained Per Subject, Time of Peak Drug Concentration Level of Dexmedetomidine and 2 more. Started Jun 2018; status: terminated.
02
Drugs
dexmedetomidine
03
Conditions
congenital heart disease (CHD)
Beyond the preview
Go deeper on NCT03417999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417999.